Last updated: September 8, 2026
Entrectinib, marketed by Roche and Genentech as Rozlytrek, is a precision oncology drug approved for ROS1-positive non-small-cell lung cancer and NTRK gene fusion-positive solid tumors. Its commercial profile is defined by a small biomarker-selected population, strong central nervous system penetration, broad geographic approval, and competition from larotrectinib and other targeted therapies.
Roche’s acquisition of Ignyta for approximately $1.7 billion in 2018 gave the company control of entrectinib and its development platform. Rozlytrek sales reached roughly CHF 0.4 billion annually by the early 2020s, but the drug remains a niche oncology product rather than a major Roche growth driver. Revenue growth depends on biomarker testing, earlier-line use, geographic expansion, and maintenance of differentiation in ROS1-positive disease. Core composition-of-matter patent protection is expected to extend into the late 2020s, with additional formulation and method-of-use protections potentially delaying commercial generic entry.
What is Entrectinib and which cancer indications does it treat?
Entrectinib is an oral tyrosine kinase inhibitor targeting the TRK family, ROS1, and ALK kinases. Its commercial value comes from activity against cancers driven by actionable gene fusions rather than from treatment of a large histologic tumor category.
| Attribute |
Entrectinib profile |
| Brand name |
Rozlytrek |
| Active ingredient |
Entrectinib |
| Developer and marketer |
Roche, Genentech |
| Original developer |
Ignyta |
| Main targets |
TRKA, TRKB, TRKC, ROS1, ALK |
| Dosage form |
Oral capsules and oral pellets |
| Main indications |
ROS1-positive metastatic NSCLC; NTRK fusion-positive solid tumors |
| U.S. approval |
August 2019 |
| European authorization |
2020 |
| Primary commercial strengths |
CNS penetration, tumor-agnostic NTRK use, ROS1 activity |
| Main competitor |
Larotrectinib, marketed as Vitrakvi |
The U.S. Food and Drug Administration approved Rozlytrek for adults with metastatic ROS1-positive NSCLC and for adults and children aged 12 years and older with solid tumors harboring an NTRK gene fusion, subject to the label’s eligibility requirements. The NTRK indication is tumor agnostic and applies where the cancer is metastatic or where surgical resection would likely produce severe morbidity and there are no satisfactory alternative treatments.[1]
Entrectinib’s CNS activity is commercially important because both ROS1-positive lung cancer and NTRK fusion cancers can involve the brain. The drug was developed with a focus on intracranial activity, which helps distinguish it from earlier kinase inhibitors with limited CNS penetration.
How has Entrectinib revenue developed?
Rozlytrek revenue has grown from a launch-stage product into a mid-sized oncology franchise, but it has not approached the scale of Roche’s leading cancer medicines.
Public Roche reporting places annual Rozlytrek sales in the approximate CHF 0.3 billion to CHF 0.5 billion range during the early 2020s. Sales increased after the initial U.S. launch as Roche expanded access across the United States, Europe, Japan, and other markets. The trajectory has been positive but constrained by the small addressable population.
| Period |
Commercial trajectory |
Primary drivers |
| 2019 |
Initial U.S. launch |
ROS1-positive NSCLC and NTRK approvals |
| 2020 |
International rollout |
European and Japanese access |
| 2021-2022 |
Continued growth |
Testing expansion, physician familiarity, CNS differentiation |
| 2023-2024 |
Mature growth phase |
Broader use in biomarker-defined disease and pediatric formulation |
| Late 2020s |
Expected pressure period |
Patent expiry, generic challenges, competitive substitution |
Roche’s broader oncology portfolio includes much larger products such as Perjeta, Kadcyla, Tecentriq, and Alecensa. Rozlytrek therefore contributes strategically as a precision-oncology asset but has limited influence on total group revenue.
The financial model is more sensitive to patient identification than to broad market share. A patient must generally pass through molecular diagnostic testing before treatment becomes possible. In NTRK disease, the mutation is rare, often occurring in less than 1% of solid tumors. ROS1 rearrangements are more common than NTRK fusions but still represent only a small percentage of NSCLC cases, generally around 1% to 2% depending on the population and testing method.[2]
What is the market size for Entrectinib?
Entrectinib addresses a high-value but narrow precision-oncology market. The product’s theoretical market includes:
- ROS1-positive metastatic NSCLC.
- NTRK fusion-positive adult solid tumors.
- NTRK fusion-positive pediatric tumors.
- Patients with CNS metastases who require a brain-penetrant therapy.
- Patients who progress after prior therapy and have no satisfactory alternative.
The limited prevalence of the relevant biomarkers constrains volume. Treatment duration can be long because patients with oncogenic driver tumors may remain on therapy until disease progression or unacceptable toxicity. This supports premium pricing and recurring revenue per patient, but it does not eliminate the population ceiling.
The most important commercial expansion lever is testing. Broader use of next-generation sequencing panels can identify fusions that would be missed by single-gene assays or histology-specific testing. However, testing rates vary substantially by country, hospital, reimbursement system, and tumor type.
Roche also benefits from the fit between entrectinib and its diagnostics and oncology infrastructure. The company can promote molecular testing, treatment pathways, and companion or complementary diagnostic use across a global cancer network.
How does Entrectinib compare with Vitrakvi and other targeted therapies?
Entrectinib versus larotrectinib
Larotrectinib, marketed as Vitrakvi by Bayer and developed with Loxo Oncology, is the closest direct competitor in NTRK fusion-positive cancer. Both drugs have tumor-agnostic NTRK indications and are used across multiple solid tumors.
| Factor |
Entrectinib |
Larotrectinib |
| Primary target profile |
TRK, ROS1, ALK |
TRKA, TRKB, TRKC |
| ROS1 indication |
Yes |
No |
| NTRK indication |
Yes |
Yes |
| CNS penetration |
Key development and commercial attribute |
Also clinically relevant |
| Pediatric use |
Approved for eligible adolescents and children |
Approved in pediatric populations |
| Commercial positioning |
Dual ROS1 and NTRK franchise |
More focused NTRK franchise |
| Main corporate owner |
Roche |
Bayer |
Entrectinib’s ROS1 indication gives it a larger commercial base than a drug limited to NTRK disease. Larotrectinib, however, has a cleaner TRK-selective profile, which can support positioning around tolerability and tumor-agnostic use.
Entrectinib versus ROS1 competitors
ROS1-positive NSCLC is increasingly competitive. Crizotinib established the first major ROS1 treatment franchise, while lorlatinib and newer ROS1 inhibitors have strengthened the treatment landscape. Competition centers on:
- intracranial response;
- activity against resistance mutations;
- durability of response;
- adverse-event management;
- sequencing after first-line therapy;
- payer positioning.
Entrectinib’s principal advantage is its clinically established CNS activity combined with broad regulatory approval. Its principal risk is displacement by next-generation ROS1 inhibitors that offer stronger activity against acquired resistance mutations or longer treatment durability.
What patents protect Entrectinib and when does exclusivity end?
Entrectinib’s U.S. intellectual-property estate includes composition-of-matter protection, pharmaceutical composition or formulation claims, and method-of-use claims covering treatment of cancers involving ROS1, NTRK, and related kinase abnormalities.
The earliest core patents trace back to development work before Ignyta’s acquisition by Roche. The expected protection timeline is approximately:
| Protection category |
Commercial relevance |
Expected timing |
| Composition of matter |
Protects the entrectinib molecule and related chemical genus |
Late 2020s |
| Salt, crystalline, or pharmaceutical composition claims |
May protect specific drug forms or dosage compositions |
Late 2020s to early 2030s, subject to validity and term adjustments |
| Method-of-use claims |
Covers treatment of ROS1-positive or NTRK fusion-positive cancers |
Varies by patent and claim scope |
| FDA regulatory exclusivity |
Blocks certain approval pathways independently of patent rights |
Primarily 2019-2026 |
| Pediatric exclusivity |
May add six months to eligible listed patents |
Depends on FDA grant and patent eligibility |
The core composition patent is generally the most important barrier. If it expires before later patents can be enforced against a proposed generic product, generic applicants may challenge the remaining claims through Paragraph IV certifications.
Exact expiration dates depend on patent term adjustment, terminal disclaimers, patent-term extension, pediatric exclusivity, and the claims listed in the FDA Orange Book. Commercial entry should therefore be modeled by patent family rather than by a single headline expiration date.
The FDA Orange Book is the controlling source for listed patents and exclusivity associated with approved small-molecule products. Roche’s patent estate should be reviewed against the current Orange Book entries, USPTO patent records, and any Paragraph IV litigation docket before an investment or launch decision.[3]
What is the Orange Book status of Rozlytrek?
Rozlytrek is an FDA-approved small-molecule product and is subject to Orange Book listing requirements for qualifying patents. The listed estate can include patents covering the active ingredient, approved formulation, dosage form, or method of use.
Orange Book exposure matters because an abbreviated new drug application applicant must address listed patents through one of four certifications:
- Paragraph I: no relevant patent information is listed;
- Paragraph II: the listed patent has expired;
- Paragraph III: the applicant will wait until patent expiration;
- Paragraph IV: the listed patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV notice can trigger a 30-month stay of FDA approval if Roche files an infringement action within the statutory period. A generic applicant can still obtain approval before the end of the 30-month period if the litigation is resolved or the stay is otherwise terminated.
Which companies are challenging Entrectinib exclusivity?
No major publicly established U.S. generic launch has displaced Rozlytrek as of the latest broadly available regulatory and company reporting. The likely challengers are large generic manufacturers with oncology portfolios and experience filing Paragraph IV certifications against high-value oral kinase inhibitors.
Potential entrants would evaluate:
- the remaining term of the core composition patent;
- whether a formulation patent covers capsules, pellets, or both;
- the scope of method-of-use claims;
- the cost of producing a complex kinase inhibitor;
- the size of the ROS1 and NTRK patient population;
- the likelihood of a settlement that permits an authorized or licensed launch.
Because the market is relatively small, a generic company may prefer a negotiated entry date over extended litigation. The same economics could encourage Roche to preserve value through authorized generic arrangements, supply agreements, or settlement structures.
What patent litigation and settlement risks affect Entrectinib?
The principal litigation risk is a Paragraph IV challenge to the core composition or formulation patents. A successful invalidity or noninfringement decision could move generic entry ahead of the expected commercial expiry date. A successful Roche action could preserve exclusivity through the asserted patent term.
Potential litigation issues include:
- Obviousness of the chemical structure and claimed kinase activity.
- Written-description and enablement support for broad genus claims.
- Infringement by a generic salt, polymorph, capsule, or pellet formulation.
- Use of entrectinib for ROS1 or NTRK disease under method-of-use claims.
- Terminal-disclaimer relationships among related patents.
- Patent-term adjustment and pediatric exclusivity calculations.
A settlement could establish a licensed generic launch date before the last patent expires. No publicly documented settlement should be assumed without confirmation from court filings, FDA records, or company disclosures.
What FDA regulatory status does Entrectinib have?
The FDA approved Rozlytrek in August 2019. The approval reflected an oncology regulatory strategy based on biomarker-defined disease, pooled clinical evidence, response rate, and duration of response rather than large randomized trials in each tumor type.[1]
Key regulatory elements include:
- ROS1-positive metastatic NSCLC approval;
- tumor-agnostic NTRK fusion-positive solid-tumor approval;
- pediatric eligibility for qualifying NTRK fusion-positive disease;
- oral capsule and pediatric pellet presentations;
- continued reliance on molecular diagnostic identification;
- potential postmarketing obligations associated with accelerated tumor-agnostic approval.
The regulatory value of the NTRK indication is greater than its prevalence would suggest because tumor-agnostic approvals can extend across multiple cancer types without requiring a separate approval for each histology.
How strong is the Entrectinib patent estate?
The estate is commercially meaningful but not immune to challenge. Its strength rests on four factors.
First, the active ingredient entered the market with a composition-of-matter patent position that should provide protection beyond the five-year new chemical entity exclusivity period.
Second, formulation claims can create additional barriers if they cover commercially necessary dosage forms, including pediatric pellets or specific solid-state forms.
Third, method-of-use claims may complicate a generic launch even after composition claims expire, although enforcement can be more difficult when generic labeling omits protected uses.
Fourth, entrectinib’s clinical use depends on biomarker-defined patients. A narrow market can reduce the economic incentive for aggressive generic litigation, but it can also make a single successful challenger disproportionately disruptive.
The estate is stronger than a product relying only on orphan exclusivity, but weaker than a biologic franchise protected by manufacturing complexity and multiple regulatory barriers. Entrectinib is a small molecule with a replicable synthetic route, so generic manufacturers can eventually reproduce the active ingredient if patent barriers fall.
What licensing deal created Roche’s Entrectinib franchise?
Roche acquired Ignyta in January 2018 for approximately $1.7 billion in an all-cash transaction. The transaction gave Roche entrectinib, Ignyta’s ROS1 and NTRK development programs, and related precision-oncology assets.[4]
The deal’s logic was strategic:
- Roche obtained a late-stage targeted oncology asset;
- entrectinib added a tumor-agnostic NTRK opportunity;
- the molecule had a separate ROS1-positive lung cancer indication;
- Roche could use its global commercialization and diagnostics infrastructure;
- the acquisition strengthened Roche’s position in biomarker-led oncology.
The transaction also transferred development risk to Roche. The company needed to establish reimbursement, expand molecular testing, manage competition, and defend the asset through the patent-expiry cycle.
What generic entry scenarios exist for Entrectinib?
Scenario 1: Delayed generic entry
A generic applicant waits until the core composition patent and relevant listed patents expire. This scenario preserves Roche revenue until the late 2020s and produces a conventional post-expiry decline.
Scenario 2: Paragraph IV settlement
A challenger files an ANDA with a Paragraph IV certification, Roche sues, and the parties agree to a licensed entry date before the final patent expiry. Revenue erosion begins on the settlement date but may be staged through one or more entrants.
Scenario 3: Early invalidity decision
A court invalidates or narrows the core patent. Multiple generic manufacturers could then enter quickly, causing a steep price and volume shift.
Scenario 4: Limited competitive erosion
Because ROS1 and NTRK populations are small and treatment is specialist-driven, some patients remain on branded Rozlytrek after generic entry. Roche could protect residual value through contracting, patient support, or an authorized generic.
For financial modeling, the most material variable is the first generic launch date. A one-year difference in entry timing can materially affect cumulative revenue because oncology products often experience rapid price erosion after multiple generic launches.
How does Entrectinib compare with Roche’s other oncology products?
Rozlytrek is strategically differentiated but financially modest compared with Roche’s largest oncology brands.
| Product |
Primary market |
Commercial scale |
Main risk |
| Rozlytrek |
ROS1 and NTRK fusion cancers |
Sub-billion-franc annual product |
Small biomarker population and patent expiry |
| Alecensa |
ALK-positive NSCLC |
Multi-billion-franc franchise |
Generic and next-generation ALK competition |
| Tecentriq |
Broad immuno-oncology |
Multi-billion-franc franchise |
Biosimilar and checkpoint competition |
| Perjeta |
HER2-positive breast cancer |
Multi-billion-franc franchise |
Biosimilar and patent-cycle pressure |
| Kadcyla |
HER2-positive cancer |
Multi-billion-franc franchise |
Biosimilar competition |
Entrectinib has no biosimilar risk because it is a chemically synthesized small molecule. Its competitive risk is generic substitution, molecular testing failure, and clinical displacement by newer kinase inhibitors.
What is the commercial outlook for Entrectinib?
The base-case outlook is stable revenue followed by gradual erosion as patents expire and ROS1 competition intensifies. The product’s strongest growth opportunities are:
- higher NGS testing rates;
- increased recognition of NTRK fusions;
- use in pediatric and rare tumor settings;
- expansion in markets with improving precision-oncology reimbursement;
- continued preference for CNS-active therapy.
The main downside factors are:
- the rarity of NTRK fusions;
- small ROS1-positive patient volume;
- competing ROS1 inhibitors;
- adverse-event management;
- payer pressure on high-cost oral oncology drugs;
- Paragraph IV challenges;
- treatment sequencing after resistance.
Revenue is unlikely to become a major Roche growth engine without a substantial new indication or a material increase in biomarker testing. Its strategic value is higher than its absolute revenue contribution because the drug supports Roche’s precision-oncology and diagnostic positioning.
Key Takeaways
- Entrectinib is a targeted oral kinase inhibitor marketed as Rozlytrek by Roche and Genentech.
- Its approved uses are ROS1-positive metastatic NSCLC and NTRK fusion-positive solid tumors.
- Roche acquired Ignyta for approximately $1.7 billion in 2018 to obtain the asset.
- Annual Rozlytrek revenue reached roughly CHF 0.4 billion during the early 2020s.
- The commercial market is constrained by rare biomarkers but supported by long treatment duration and premium oncology pricing.
- Larotrectinib is the closest NTRK competitor, while newer ROS1 inhibitors pose a growing threat in lung cancer.
- Core patent protection is expected to extend into the late 2020s, subject to patent-term adjustments and Orange Book listings.
- Generic entry is likely to depend on Paragraph IV litigation, settlement timing, and the strength of formulation and method-of-use claims.
- Entrectinib has generic rather than biosimilar exposure because it is a small-molecule drug.
- The product is strategically important to Roche’s precision-oncology portfolio but is unlikely to become a top-tier group revenue driver.
FAQs about Entrectinib market and exclusivity
Is Entrectinib a biologic or a generic drug?
Entrectinib is a chemically synthesized small-molecule drug. It is not a biologic and therefore faces ANDA-based generic competition rather than biosimilar competition.
Why is Entrectinib used for NTRK fusion cancers?
NTRK gene fusions can create abnormal TRK kinase signaling that drives tumor growth. Entrectinib inhibits TRKA, TRKB, and TRKC and can treat cancers harboring these fusions across different tumor histologies.
Does Entrectinib work against brain metastases?
Entrectinib was developed for CNS penetration and has demonstrated intracranial activity. The extent of benefit depends on tumor biology, prior treatment, disease burden, and resistance mechanisms.
What is the biggest commercial risk for Rozlytrek?
The main risk is the combination of a small biomarker-defined market and future generic or competing targeted-therapy entry. In ROS1-positive NSCLC, newer inhibitors may reduce use before patent expiry.
Can Roche extend Entrectinib exclusivity beyond the core patent?
Roche may rely on formulation, dosage-form, method-of-use, patent-term adjustment, pediatric exclusivity, and settlement rights. The practical exclusivity date depends on the enforceable claims listed in the Orange Book and the outcome of any Paragraph IV litigation.
References
- U.S. Food and Drug Administration. (2019). FDA approves entrectinib for NTRK solid tumors and ROS-1 positive non-small cell lung cancer. https://www.fda.gov
- Drilon, A., Laetsch, T. W., Kummar, S., et al. (2018). Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New England Journal of Medicine, 378(8), 731-739.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- Roche. (2018). Roche to acquire Ignyta, Inc. for approximately $1.7 billion. https://www.roche.com
- Roche. (2023). Annual report 2023. https://www.roche.com/investors/annual-report
- Genentech. (2024). Rozlytrek prescribing information. https://www.gene.com/download/pdf/rozlytrek_prescribing.pdf
